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Abstract
Purpose—Some Epstein-Barr virus (EBV)-directed therapies are predicted to be effective only
when lytic viral replication occurs. We studied whether cyclophosphamide chemotherapy induces
EBV to switch from latent to lytic phases of infection in a series of EBV-associated Burkitt
lymphomas.
Experimental Design—Children with first presentation of an expanding, solid maxillary or
mandibular mass consistent with Burkitt lymphoma underwent fine needle aspiration just prior to
initiation of cyclophosphamide and again 1 to 5 days later. Aspirated cells were examined for latent
and lytic EBV infection using in situ hybridization to EBV-encoded RNA (EBER),
immunohistochemical analysis of the lytic EBV proteins BZLF1 and BMRF1, reverse transcription
PCR targeting BZLF1 transcripts, and EBV viral load measurement by quantitative PCR.
Results—Among 21 lymphomas expressing EBER prior to chemotherapy, 9/10 still expressed
EBER on day 1 after therapy while only 2/11 (18%) specimens still expressed EBER at days 3 to 5,
implying that chemotherapy was fairly effective at eliminating latently infected cells. Neither of the
lytic products, BZLF1 or BMRF1, was significantly upregulated at the post-therapy time-points
examined. However, EBV genomic copy number increased in 5/10 samples 1 day after treatment
began, suggesting that viral replication occurs within the first 24 hours.
Conclusion—Cyclophosphamide may induce the lytic phase of EBV infection and is fairly
effective in diminishing EBER-expressing tumor cells within 5 days. These findings provide the
Corresponding author and reprint requests: Margaret L. Gulley, MD, Dept of Pathology and Laboratory Medicine, University of North
Carolina, 101 Manning Dr, 913 Brinkhous-Bullitt Building, Chapel Hill, NC 27599-7525, margaret_gulley@med.unc.edu.
Translational Relevance: The presence of Epstein-Barr virus (EBV) genome within malignant cells of endemic Burkitt lymphoma
makes EBV an appealing target for therapy. Mechanistic data in cell lines and mouse models suggests that ganciclovir enhances tumor
cell killing by chemotherapy only if the chemotherapy induces lytic viral replication. Our prospective study of naturally infected African
Burkitt lymphoma patients found evidence of viral replication within the first 24 hours after starting cyclophosphamide. This result
supports design of a phase two trial of cyclophosphamide and ganciclovir in endemic Burkitt lymphoma.
NIH Public Access
Author Manuscript
Clin Cancer Res. Author manuscript; available in PMC 2011 April 1.
Published in final edited form as:













rationale for a trial testing synergistic tumor cell killing using cyclophosphamide with a drug like
ganciclovir targeting lytically infected cells.
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Introduction
Epstein–Barr virus (EBV) is a human gamma herpes virus that establishes a persistent infection
in more than 90% of the world’s population. EBV DNA has been detected in numerous tumors
including Hodgkin and non-Hodgkin lymphomas, undifferentiated nasopharyngeal carcinoma,
gastric carcinoma, and primary brain lymphomas in AIDS patients. EBV is closely associated
with endemic Burkitt lymphoma in sub-Saharan Africa.
Like other herpes viruses, EBV exists inside cells in two alternative modes: latent infection
and lytic replication (1). In the latent form of infection, EBV persists largely within memory
B lymphocytes where only a small fraction of viral genes are expressed including EBV-
encoded RNA (EBER). Upon cell division, replication of the viral genome is mediated by host
cell DNA polymerase (1). The lytic form of infection is required for packaging of virions
permitting transmission from host to host. In the lytic phase, most viral genes are expressed in
a carefully orchestrated sequential fashion mediating viral genomic replication, encapsidation,
and release of infectious virions accompanied by lysis and death of the host cell (2).
Induction of EBV replication can be achieved using radiation therapy, chemotherapy, or other
manipulations inducing the lytic phase (3–6). Lytic phase infection promotes destruction of
EBV-positive tumor cells, at least in cell culture models and in transgenic mouse models (7–
12). It is timely and important to translate successful laboratory models into clinical practice.
Latently infected malignancies such as Burkitt lymphoma may respond to lytic induction with
associated host cell death. In fact, lytic cell death may be even more effective in vivo than in
vitro when immune recognition of foreign viral antigens contributes to cell destruction.
A clinical trial by Chan and colleagues explored feasibility of lytic induction by azacytidine
in ten patients with various EBV-related malignancies (13). Azacytidine is a DNA
methyltransferase inhibitor that reactivates transcription of genes that were silenced by CpG
island methylation. When administered to patients, there was significant demethylation of CpG
islands in promoters of latent and lytic EBV genes encoding immunogenic proteins. By
immunohistochemistry, only one patient had detectable lytic protein expression, suggesting
that the effect was minimal, transient, or promptly progressed to cell death (13).
Histone deacetylase (HDAC) inhibitors such as sodium butyrate are well known inducers of
lytic replication in Burkitt lymphoma cell lines (6,14,15). A clinical trial of the HDAC inhibitor,
romidepsin, in T cell lymphoma patients resulted in secondary EBV-related
lymphoproliferations in two of 120 treated patients (16). While these lymphoproliferations are
likely to be multifactorial, it is feasible that HDAC inhibitors and other chemotherapeutic
agents initiating lytic replication (like methotrexate (17)) could function to enhance killing of
EBV-related neoplasia at a cost of increasing risk of secondary EBV-related
lymphoproliferations. Interestingly, withdrawl of methotrexate therapy usually leads to
regression of the associated EBV-driven lymphoproliferation, presumably by relieving the
drug’s immunosuppressive effect (18).
If lytic cycle inducers could be rendered even more potent, perhaps they might be capable of
eliminating every malignant cell of an infected tumor. Intriguing studies show that some lytic
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phase proteins (e.g. EBV thymidine kinase and BGLF4) can phosphorylate nucleoside analog
drugs like ganciclovir to a toxic form, enhancing killing of the host cell and also of surrounding
cells (e.g. latently infected tumor cells) (3,10,19,20). Therefore, addition of nucleoside analog
drugs may achieve outcomes beyond what could be achieved with cytotoxic therapy alone. In
a clinical trial of arginine butyrate plus ganciclovir in 15 patients with EBV-related lymphoma,
four patients had complete response and 6 others had partial response (21). Most responses
occurred within the first week of therapy, and tumor lysis was unexpectedly rapid in several
patients (21).
Whether there is synergy between traditional chemotherapy and nucleoside analog therapy in
Burkitt lymphoma patients remains to be tested. Burkitt lymphoma is the most common lethal
malignancy of children between the ages of 3 to 15 years in the tropical regions of Africa, and
this cancer is nearly always EBV-associated (22–24). In nearly all cases, the EBV gene
expression pattern is very restricted. LMP1 and LMP2 are not expressed and, due to Qp
promoter usage for EBNA1 transcription, only EBNA1 but not the other EBNAs are expressed
(25,26). In resource-poor settings in Africa, Burkitt lymphoma is often treated using single
agent cyclophosphamide with survival rates of 64% among children with maxillary or
mandibular tumors compared to only 33% for those having more disseminated disease (25,
27,28).
Despite the potential for application to human disease, it has yet to be proven that chemotherapy
induces lytic EBV gene expression in vivo in Burkitt lymphoma patients. Demonstrating lytic
EBV expression in tumor tissue following treatment with chemotherapy may justify a new
combined therapeutic approach to treating EBV-related malignancies. In the current study, we
examined the extent to which lytic replication is induced by single agent cyclophosphamide
in African children with Burkitt lymphoma. Fine needle aspirates of tumor were collected
before and again 1 to 5 days after initiation of cyclophosphamide therapy, and the specimens
were examined for evidence of latent and lytic EBV infection using histochemical and
molecular methods. Our findings lay the groundwork for a possible clinical trial testing the




This research was approved by the UNC Medical Institutional Review Board and the Malawi
National Health Sciences Research Committee. Consent was obtained from each patient’s
guardian. Children were admitted to the pediatric Burkitt Lymphoma ward of Kamuzu Central
Hospital in Lilongwe, Malawi from August 2007 to June 2008. Patients age 3 to 15 years were
recruited if they had a rapidly expanding mass involving the maxilla or mandible that was
superficial and amenable to safe biopsy. All patients were studied at initial presentation of
disease, and none had a previous history of cancer or cancer treatment. All patients were
scheduled to receive cyclophosphamide therapy. Patients were excluded if they had
hemoglobin <8g/dL, platelets <50,000/uL, or known intolerance or allergy to lidocaine. One
study-specific pediatrician (CW) performed all fine needle aspirate (FNA) procedures.
Treatment plans did not change as a result of enrollment. Patients were treated with
cyclophosphamide 40mg/kg IV, with a plan to repeat every 2 weeks for at least 6 cycles.
Prior to the first round of cyclophosphamide, the skin overlying the mandibular or maxillary
mass was anesthetized with topical 2.5% lidocaine and 2.5% prilocaine (EMLA cream,
AstraZeneca) and an FNA obtained using a 23-gauge needle. The aspirated material was
promptly transferred into a vial containing 20 mL of PreservCyt solution (Hologic, Inc.,
Bedford, MA), pumping the syringe several times to rinse. In the first half of the study, the
Tang et al. Page 3













aspiration procedure was repeated 3 to 5 days after initiation of the first round of
cyclophosphamide therapy. After interim analysis of laboratory data, subsequent patients had
their second aspiration on day 1 rather than on day 3 to 5 to test whether viral replication
occurred earlier in the time course following initiation of treatment. Specimens were
refrigerated for up to six weeks before shipment in batches to University of North Carolina at
Chapel Hill where 10 mL of the aspirate was used to make a paraffin- embedded cell block
and the remaining 10 mL was used for nucleic acid extraction.
In situ hybridization
To localize latently infected cells, in situ hybridization was performed using an EBER probe,
with an oligo-dT probe run in parallel as an RNA preservation control, on a BenchMark XT
system (Ventana Medical System, AZ) according to manufacturer instructions. Results were
interpreted by two pathologists (MLG and WT) who characterized each specimen as having
abundant, few or no detectable EBER-expressing cells. Nuclear EBER signal was considered
legitimate evidence of EBV infection. The proportion of EBER-expressing cells was calculated
based on counts of EBER-positive cells and total nucleated cells in three 40x microscopic fields.
Real-time polymerase chain reaction (PCR) to measure EBV viral load
To measure EBV genomic copy number, quantitative PCR targeting the BamH1W segment
was performed on DNA extracted from scrolls of each paraffin embedded cell block using the
QIAamp DNA Mini Kit (QIAGEN, Inc). In 4 subjects there was insufficient DNA in the
paraffin embedded sample so total nucleic acid was extracted from PreservCyt-suspended cells
using the the QIAamp DNA Mini Kit. Viral load was measured as previously described (29)
on an ABI 7500 real time PCR instrument using primers and a TaqMan probe targeting the
EBV BamH1W segment in duplex with an assay targeting the human APOB gene that serves
as a normalizer for the number of cells represented in the reaction. DNA from the Namalwa
Burkitt lymphoma cell line was used as a standard by which to quantitate both EBV and
APOB (29). EBV genomic copy number was reported as EBV copies per 100,000 cells.
Quantitative-rtPCR to detect EBV lytic gene expression
EBV lytic gene expression was detected by quantitative reverse transcription PCR (Q-rtPCR)
targeting BZLF1 mRNA. First, RNA was extracted from 10 mL of FNA preservative using the
RNeasy Mini Kit (Qiagen) and DNA was removed by on-column deoxyribonuclease digestion
for 15 min at room temperature using the RNase-Free DNase Set (Qiagen). Total RNA was
eluted into 30 μL of ribonuclease-free water and cDNA was synthesized immediately using
random hexamers and the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City,
CA). RNA preservation and cDNA quality was confirmed using Q-rtPCR targeting human
ABL1 exons 10 and 11. Primers and TaqMan probes listed in Table 1 were chosen to span
introns so that any residual genomic DNA would be unlikely to amplify (30). Positive controls
included RNA from the B95.8 and Namalwa cell lines. No template controls verified absence
of amplicon contamination.
Immunohistochemistry to detect EBV lytic gene expression
To detect EBV lytic protein expression in cell blocks, immunohistochemistry was performed
using antibodies targeting the immediate-early lytic protein BZLF1 and the early lytic protein
BMRF1. Briefly, unstained sections were deparaffinized, rehydrated and then incubated
overnight at 4°C in monoclonal antibody targeting either BZLF1 (ZEBRA, M7005, DAKO
Corporation, Carpinteria) or BMRF1 (Clone#:G3-E31, Fitzgerald, MA) using the blocking and
detection protocols in the Super-Sensitive Non Biotin HRP Detection Kit (Biogenex). Oral
hairy leukoplakia was used as a positive control for both lytic proteins. A control stain of the
B cell marker CD20 (Chemicon international, Temecula, CA) was run in parallel to verify
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protein detectability in each specimen. Results were interpreted by two pathologists (MLG and
WT) who characterized each specimen as having abundant, few or no detectable BZLF1 or
BMRF1-expressing cells.
Statistical analysis
Association of EBER positivity between 1 day and 3–5 day treatment groups was assessed
using a chi-square test. Exact Wilcoxon rank-sum tests were used to compare differences in
median viral loads and median EBER-expressing cell proportions, respectively, between
specimens collected on treatment day 1 versus specimens collected on days 3–5 (SAS 9.2, SAS
Institute Inc, Cary, NC).
Results
Clinical and cytological features
Thirty-three patients ranging from 4 to 14 years old with 20 males and 13 females were enrolled.
Only those patients confirmed to have EBV-related Burkitt lymphoma based on clinical and
cytologic features were further studied.
The first 16 enrolled patients had a second FNA collected 3–5 days after starting the first round
of cyclophosphamide. Five of the 16 patients were excluded because initial hemoglobin was
<8g/dL (n=1), the subject left the hospital before the second FNA was done (n=1), or FNA
was EBER-negative at both time-points (n=3). Among the latter three subjects with EBER-
negative aspirates, the first had cytologic features of an EBER-negative diffuse large cell
lymphoma, the second had rare atypical large cells in a background of acute and chronic
inflammation, and the third had reactive-appearing mixtures of inflammatory cells. Further
evaluation would be required to distinguish reactive or infectious processes from Hodgkin
lymphoma, non-Hodgkin lymphoma, or other tumor types.
The next 17 enrolled patients had a second FNA collected only one day after starting the first
round of cyclophosphamide. Seven of the 17 were excluded because initial hemoglobin was
<8g/dL (n=1), an FNA sample was lost (n=1), or the initial FNA was EBER-negative (n=5).
Among the latter five patients with EBER-negative aspirates, the first had multinucleated giant
cells and abundant eosinophils, the second had a few CD20-negative large cells and many
macrophages, and the next three patients had peripheral blood although the post-treatment
aspirate of one patient contained scattered EBER-positive large cells suggesting that the needle
had missed an EBER-expressing tumor in the pre-treatment sampling. Overall, a total of 21
patients had adequate FNAs before and after chemotherapy. There were no complications.
The 21 patients confirmed to have EBV-related Burkitt lymphoma based on clinical and
cytologic features combined with EBER-positivity ranged from 5 to 14 years old with 13 males
and 8 females. Typical cytologic features included enlarged lymphoid cells, fine granular blast-
like chromatin, and tingible body-laden macrophages, all of which are characteristic of Burkitt
lymphoma. CD20 was expressed in larger atypical lymphoid cells in all cases (Figure 1).
EBER expression is diminished or lost after therapy
Latent EBV infection was identified by EBER in situ hybridization in all 21 specimens collected
before therapy was initiated. As shown in Table 2, EBER was still expressed in nearly all
specimens collected 1 day after treatment. By 3–5 days after treatment, EBER was undetectable
in the majority of patients (Figure 1). The difference is statistically significant (p = 0.0019).
Total nucleated cell number was visibly decreased in all post-therapy specimens compared to
pre-treatment levels. There was often a lower proportion of atypical lymphoid cells and, in
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some cases, no cytomorphologic evidence of malignancy in the post-therapy specimens.
EBER-expressing cells were only rarely visible by microscopy in patients sampled 3–5 days
after therapy. In contrast, EBER-expressing cells were easily identified in all but one patient
(#15) sampled on day 1 after therapy. (See Table 3.) These findings suggest that
cyclophosphamide has a rapid effect in diminishing latent infection to nearly undetectable
levels in the majority of patients within 5 days after initiation of treatment.
EBV DNA levels implicate viral replication after chemotherapy
Human APOB gene copy number was measured by real-time PCR as a surrogate for the number
of nucleated cells represented in each DNA amplification reaction. APOB results helped adjust
for fact that the number of cells aspirated differed from specimen to specimen. APOB levels
typically went down after therapy (average 2-fold decrease), which correlates with the
cytologic observation of fewer nucleated cells after treatment.
EBV viral load in tumor aspirates was measured by real-time PCR, and the results were
rendered quantitative by virtue of normalization to the number of nucleated cells as represented
by the human APOB gene results. EBV viral load was high in all 21 lymphoma specimens
tested at the time of initial diagnosis before starting therapy. As shown in figure 2, EBV load
fell precipitously in the 11 samples that were aspirated 3–5 days after treatment (average 9-
fold loss of EBV). However, in specimens collected just one day after therapy, EBV viral load
often did not decrease substantially compared with diagnostic specimens, and in fact it
increased in half of the specimens (5 of 10 cases; Table 4.) The average increase in EBV load
was 30-fold in the ten tumors sampled at day 1 compared to pretreatment levels. Even after
excluding the outlier subject (case #16) with an exceptionally high rise in EBV load, the average
viral load still rose 8-fold among tumors sampled at day 1 compared to pretreatment levels.
An increase in EBV load suggests that the EBV genome has replicated during the first day
after initiation of chemotherapy. This rise in viral load, in the face of diminishing numbers of
cells, is consistent with lytic viral replication.
EBV lytic gene BZLF1 expression is detected in few Burkitt lymphoma tissues
To test whether lytic infection was the explanation for increased EBV viral load immediately
after treatment, viral lytic gene expression was examined by Q-rtPCR targeting the EBV lytic
transcript, BZLF1. BZLF1 is normally expressed very early in lytic phase and is considered to
be the master switch controlling exit from latency to lytic viral replication.
Extracted RNA was successfully amplified in all specimens using PCR with a TaqMan probe
targeting an endogenous control transcript (human ABL1 mRNA). BZLF1 transcripts were
expressed in only four samples, 3 collected before initiation of therapy (from patient #4, #11,
and #19) and only one collected after therapy. The latter, from patient #12, was aspirated on
day 1 after therapy and expressed low-level BZLF1. Overall, these data suggest no significant
up-regulation of this lytic viral factor at the post-therapy time-points examined.
All three of the tumors having evidence of lytic infection prior to therapy had dramatic drops
in EBV viral load after chemotherapy.
EBV lytic proteins were not expressed by immunohistochemistry
To further characterize any lytic infection, immunohistochemistry was performed using
monoclonal antibodies against BZLF1 and BMRF1 which represent markers of lytic EBV
infection. Microscopic examination revealed no detectable expression of either protein in any
of the pre- or post-therapy aspirates. Control staining showed successful detection of both
proteins in oral hairy leukoplakia tissue. Furthermore, each aspirate in this study was
successfully stained for a protein (CD20) that is ubiquitously expressed in normal and
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malignant B lymphocytes, diminishing the likelihood that technical failure is responsible for
the negative viral lytic expression results in these aspirates. These data suggest that our
immunohistochemical method is not sensitive enough to detect these lytic proteins, or that the
timing of specimen collection was not optimal for detecting transient expression of these
factors. It should be noted that BZLF1 is an immediate early lytic factor and BMRF1 is an
early factor, meaning that both are expressed at an early time-point during the sequential
process of viral replication and cell lysis.
Discussion
This study found EBV DNA levels, as measured by Q-PCR, frequently rise within one day of
the start of cyclophosphamide therapy for Burkitt lymphoma. By day 5, the viral load and the
tumor burden are already greatly diminished. The initial rise in EBV levels in some day 1
tumors could reflect viral DNA replication. The mechanism of EBV DNA replication is
hypothesized to be lytic infection, although evidence for expression of the early viral genes
BZLF1 and BMRF1 was lacking at the time-points that were examined.
The lytic phase of EBV infection is normally marked by sequential expression of a cascade of
proteins that co-opt cellular functions leading to replication of the viral genome followed by
packaging of viral DNA and export of infectious virions (1). The earliest marker of lytic viral
infection is expression of the immediate-early protein, BZLF1, followed by other early markers
such as BMRF1 (11,31,32). These lytic genes are usually silent or are expressed only focally
at low level in Burkitt lymphoma tissues (4,26).
The current study confirmed that BZLF1 and BMRF1 were not expressed in Burkitt lymphoma
by immunohistochemistry, although the more sensitive rtPCR method revealed BZLF1 in 3/21
pretreatment tumors. Our study is the first to examine expression of these lytic factors in the
first few days after initiation of chemotherapy. We showed low-level expression of BZLF1,
detectable only by a sensitive rtPCR assay, in only one post-therapy aspirate. Despite a general
lack of evidence for replicative gene expression, EBV viral load increased above pre-treatment
levels in 50% of day-one aspirates, implying that viral replication had already occurred within
the first 24 hours of treatment. Viral load then fell but remained detectable at days 3 to 5. It is
uncertain how much of the remaining viral DNA is intracellular versus packaged in virions or
existing as naked viral genomes from dying tumor cells.
The time-course of events implies that replicative infection could be initiated within hours of
exposure to cyclophosphamide. In cell line models, Countryman et al showed that the kinetics
of lytic induction depends on the host cell type and the dose and timing of the stimulus (33).
In the Akata Burkitt lymphoma cell line stimulated by crosslinking surface immunoglobulin
receptors, Wen et al showed that BZLF1 mRNA was expressed as early as 1.5 hours and
disappeared in 24 hours, while the encoded protein was expressed from 6 to 12 hours after
induction (5). In humans, we found it difficult to track the kinetics of replicative infection.
After enrolling our first cohort of Burkitt lymphoma patients and finding no replicative gene
expression at time-points of 3 to 5 days, we proceeded to enroll additional patients for
evaluation just one day after initiation of therapy and we still seem to have missed the putative
window of replicative viral gene upregulation, although we were able to demonstrate viral load
increases implicating lytic phase of infection. Re-biopsy at multiple time-points is difficult, so
a detailed timeline of tumor-based profiles is probably not feasible in humans.
We hypothesize that transient expression of lytic proteins permits viral DNA synthesis while
simultaneously triggering immune recognition of foreign immunogenic peptides leading to
engulfment by macrophages, which contributes to the “starry sky” histology that is
characteristic of Burkitt lymphoma. Lytic infection is notoriously difficult to document, even
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in oropharyngeal tissues where replicative infection occurs routinely as evidenced by periodic
shedding of virions into saliva (34).
In the current study, the proportion of EBER expressing cells was similar to baseline at days 1
and 3, although by days 4 to 5 all specimens had undetectable EBER in concert with the
disappearance of malignant-appearing cells. In future studies, one could explore whether the
initial response to chemotherapy, in terms of serially measured viral loads or infected cell
counts, predicts long term outcome. Because blood sampling is less invasive than tumor
aspiration, circulating markers of latent and replicative viral infection should be examined
(35,36).
The observed decline in EBER-expressing cells could result from elimination of infected tumor
cells or from EBER downregulation in tumor cells. Lytic infection is associated with diminished
EBER expression, at least in some lesions and cell models (37,38). Although transcriptional
regulation of EBER genes is poorly understood, recent evidence shows that MYC can bind to
and activate the EBER1 gene promoter (39–41). Promoter methylation is a proposed
mechanism for silencing EBER1 and EBER2 transcription (37,42). Altered availability or
enhanced degradation of EBERs must also be considered as potential cause of diminished
EBER expression (43). Relief from EBV’s tumorigenic and antiapoptotic effects might explain,
at least in part, the efficacy of chemotherapy.
The anti-tumor effect of cyclophosphamide therapy is dramatic, and its introduction to clinical
medicine beginning over 50 years ago represents one of the great historic breakthroughs in
cancer management (44). Nevertheless, a significant fraction of treated patients eventually
relapse and die. Clearly more effective therapies are needed for Burkitt lymphoma and for other
EBV-related malignancies that, in aggregate, are estimated to affect about 1% of the world’s
population. EBV is an appealing therapeutic target because it is likely to be involved in
pathogenesis of the neoplasm and, when present, it is generally found within every malignant
cell of a given infected malignancy (4,10,45–47). Considerable work has been done to explore
the possibility of destroying EBV-infected cells by means of inducing lytic infection (7–10,
13,46,48–50). Infection terminating in cell lysis or immune destruction is an appealing
endpoint for cancer therapy.
In conclusion, we found evidence supporting EBV lytic induction in Burkitt lymphoma patients
almost immediately after the first dose of cyclophosphamide, a drug that is very commonly
used in Africa as single agent therapy. Evidence of lytic replication lays the groundwork for a
clinical trial testing the efficacy of adding a nucleoside analog to enhance cancer-specific
cytotoxicity of cyclophosphamide.
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Figure 1. Cytologic and histochemical features demonstrate loss of EBER-expressing Burkitt
lymphoma cells after cyclophosphamide therapy
(A) In a newly diagnosed patient, hematoxylin and eosin stain reveals features of Burkitt
lymphoma including atypical lymphoid cells with fine, blast-like chromatin, and a large cell-
laden macrophage in the lower left. (B) Immunohistochemistry reveals CD20 localized to
cytoplasm and membrane of atypical cells. (C) EBER is expressed by in situ hybridization in
many nuclei, whereas smaller lymphoid cells stain only with the eosin counterstain; (D) In an
aspirate from the same patient 4 days after start of chemotherapy, EBER is not expressed while
a control hybridization targeting oligo-dT (inset) shows RNA is preserved in most cells.
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Figure 2. EBV viral load may increase initially but then falls consistently in post-therapy tumor
specimens
EBV viral load, expressed in copies per 100,000 cells, is displayed as mean with standard error
bars in each clinical subgroup of Burkitt lymphomas. Both pre-treatment groups have similar
distributions of viral burden. Mean viral load is even higher among tumors sampled on day
one, but has declined by days 3 to 5 after start of chemotherapy.
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Table 1







 Forward primer 5′-acgcacaccgaaaccacaa-3′ 90,397-90,379





Position in the EBV genome relates to NCBI Accession number AJ507799
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Table 2
Frequency of latent EBV detection in tumors before and after start of cyclophosphamide therapy
Before Therapy
After Therapy*
Day 1 (n=10) Days 3–5 (n=11)
Positive EBER stain 21 9 2
Negative EBER stain 0 1 9
*
Results are significantly different in day 1 versus day 3–5 collections, p value = 0.0019
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